Literature DB >> 22669290

Physiologically based pharmacokinetic (PBPK) modeling in children.

J S Barrett1, O Della Casa Alberighi, S Läer, B Meibohm.   

Abstract

This review summarizes the present status of physiologically based pharmacokinetic (PBPK) modeling and simulation (M&S) and its application in support of pediatric drug research. We address the reasons that PBPK is suited to the current needs of pediatric drug development and pharmacotherapy in light of the evolution in pediatric PBPK methodologies and approaches, which were originally developed for the purpose of toxicologic evaluation. Also discussed is the current degree of confidence in using PBPK to support pediatric drug development and registration and the key factors essential for robust results and broader adoption of pediatric PBPK M&S.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22669290     DOI： 10.1038/clpt.2012.64

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  65 in total

1.  Organ data from the developing Göttingen minipig: first steps towards a juvenile PBPK model.

Authors:  Els Van Peer; Noel Downes; Christophe Casteleyn; Chris Van Ginneken; Arie Weeren; Steven Van Cruchten
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-12-19       Impact factor: 2.745

2.  Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation.

Authors:  Radojka M Savic; Morton J Cowan; Christopher C Dvorak; Sung-Yun Pai; Luis Pereira; Imke H Bartelink; Jaap J Boelens; Robbert G M Bredius; Rob F Wynn; Geoff D E Cuvelier; Peter J Shaw; Mary A Slatter; Janel Long-Boyle
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-09       Impact factor: 5.742

3.  Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates.

Authors:  Wei Zhao; Valérie Biran; Evelyne Jacqz-Aigrain
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

Review 4.  Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.

Authors:  Lei Diao; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

5.  Determination of intracellular fludarabine triphosphate in human peripheral blood mononuclear cells by LC-MS/MS.

Authors:  Liusheng Huang; Patricia Lizak; Francesca Aweeka; Janel Long-Boyle
Journal:  J Pharm Biomed Anal       Date:  2013-08-23       Impact factor: 3.935

Review 6.  State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development.

Authors:  Venkata Yellepeddi; Joseph Rower; Xiaoxi Liu; Shaun Kumar; Jahidur Rashid; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2019-01       Impact factor: 6.447

7.  Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling.

Authors:  Deni Hardiansyah; Chee Meng Ng
Journal:  MAbs       Date:  2018-07-30       Impact factor: 5.857

8.  Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults.

Authors:  Guo-Fu Li; Qing-Shan Zheng; Yichao Yu; Wei Zhong; Hong-Hao Zhou; Furong Qiu; Guangji Wang; Guo Yu; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

Review 9.  Clinical pharmacology in neonates: small size, huge variability.

Authors:  Karel Allegaert; John N van den Anker
Journal:  Neonatology       Date:  2014-05-30       Impact factor: 4.035

10.  A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.

Authors:  Jing-Tao Lu; Ying Cai; Feng Chen; Wei-Wei Jia; Zhe-Yi Hu; Yuan-Sheng Zhao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.